Talking Medicines, a pioneering force in AI-driven healthcare marketing, is reshaping how pharmaceutical companies engage with Healthcare Professionals and patients. Based in Glasgow, Scotland, the company harnesses advanced data science and natural language processing to extract actionable insights, driving more effective and patient-centric marketing strategies.
Founded in 2013, Talking Medicines has revolutionised data intelligence with its flagship product, Drug-GPT. This innovative tool processes unstructured data, providing pharmaceutical companies with unparalleled clarity on patient and Healthcare Professional experiences. By refining marketing approaches based on real-world feedback, Talking Medicines empowers the industry to deliver more personalised and impactful healthcare solutions.
Breaking into the US Market
Talking Medicines is set to accelerate its global expansion as one of five leading Scottish companies selected for Scottish Enterprise’s US MarketBooster Programme. This initiative is a game-changer, designed to propel Scottish science and tech firms into the highly competitive US landscape. For Talking Medicines, this marks a major milestone, enhancing its scalability and reinforcing its presence in the world’s largest technology market.
Scottish Enterprise is committed to doubling the number of scaling companies in Scotland over the next decade. By offering comprehensive support, the US MarketBooster Programme equips companies with the expertise, networks, and skills essential for thriving in the US. This initiative aligns perfectly with Talking Medicines’ ambition to strengthen its foothold and accelerate growth in the healthcare marketing space.
Fast-Tracking US Growth
The US MarketBooster Programme is poised to be a catalyst for Talking Medicines’ expansion. Co-founder Jo Halliday acknowledges the vital role of Scottish Enterprise in the company’s journey, stating:
“We’ve been supported by Scottish Enterprise over the years in many useful ways, and their help means you can go further, faster, and bring the benefit into your business and bottom line sooner.
We’re very excited to be involved in this programme alongside other scaling companies looking to expand and go big in the United States. Talking Medicines already has a successful presence in the US, and this programme will further accelerate our scalability in 2025 through the extension of our current market and growth of AI.”
Scottish Innovation Leading Healthcare Data Transformation
Talking Medicines’ participation in the US MarketBooster Programme underscores Scotland’s thriving tech ecosystem. Positioned alongside leading companies in AI, cloud computing, and cybersecurity, Talking Medicines exemplifies cutting-edge innovation in healthcare data intelligence.
By leveraging the strategic backing of Scottish Enterprise and Silicon Valley networks, Talking Medicines aims to achieve US revenue growth at an accelerated pace. This programme provides a unique opportunity to fast-track success, ensuring the company remains at the forefront of healthcare marketing transformation.
A Bold Step Towards Global Impact
Talking Medicines’ expansion into Silicon Valley is a defining moment in its mission to revolutionise healthcare marketing through AI and data intelligence. With the invaluable support of the US MarketBooster Programme, the company is poised to make a lasting impact, driving innovation, scalability, and patient-centred insights in the US healthcare market.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams. The Talking Medicines mission is to be the World’s Gold Standard for Patient Intelligence by Medicine.
